title: Conditional deletion of cardiomyocyte peroxisome proliferator-activated receptor γ enhances myocardial ischemia-reperfusion injury in mice.
abstract: The nuclear transcription factor peroxisome proliferator-activated receptor γ (PPARγ) is a key regulator of the inflammatory response to an array of biologic insults. We have previously demonstrated that PPARγ ligands reduce myocardial ischemia-reperfusion injury in rodents. In the current study, we directly determined the role of cardiomyocyte PPARγ in ischemia-reperfusion injury, using a model of conditional cardiomyocyte-specific deletion of PPARγ in vivo. In mice, α-myosin heavy chain-restricted Cre-mediated PPARγ deficiency was induced by tamoxifen treatment (30 mg/kg intraperitoneally) for 4 days (PPARγ mice), whereas controls included mice treated with the oil diluent vehicle (PPARγ mice). Western blot and histochemical analyses confirmed that expression of PPARγ protein was abolished in cardiomyocytes of mice treated with tamoxifen, but not with vehicle. After tamoxifen or vehicle treatment, animals were subjected to 30-min ligation of the left anterior descending coronary artery followed by 2-h reperfusion. In PPARγ mice, myocardial ischemia and reperfusion induced extensive myocardial damage, which was associated with elevated tissue activity of myeloperoxidase, indicating infiltration of neutrophils, and elevated plasma levels of troponin I when compared with PPARγ mice. Upon echocardiographic analysis, PPARγ mice also demonstrated ventricular dilatation and systolic dysfunction. Plasma levels of the proinflammatory cytokines interleukin 1β and interleukin 6 were higher in PPARγ mice when compared with PPARγ mice. These pathological events in PPARγ mice were associated with enhanced nuclear factor κB DNA binding in the infarcted hearts. Thus, our data suggest that cardiomyocyte PPARγ is a crucial protective receptor and may prevent reperfusion injury by modulating mechanisms of inflammation.
authors.affiliation: *Division of Critical Care Medicine and †Cardiovascular Imaging Core of the Heart Institute, Cincinnati Children's Hospital Medical Center, and The University of Cincinnati College of Medicine, Cincinnati, Ohio.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Hobson
authors.forename: Paul W
authors.initials: PW
authors.lastname: Hake
authors.forename: Michael
authors.initials: M
authors.lastname: O'Connor
authors.forename: Christine
authors.initials: C
authors.lastname: Schulte
authors.forename: Victoria
authors.initials: V
authors.lastname: Moore
authors.forename: Jeanne M
authors.initials: JM
authors.lastname: James
authors.forename: Giovanna
authors.initials: G
authors.lastname: Piraino
authors.forename: Basilia
authors.initials: B
authors.lastname: Zingarelli
mesh_terms: D000818:Animals; D016207:Cytokines / Q000097:blood; D004268:DNA-Binding Proteins / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D015428:Myocardial Reperfusion Injury / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D032383:Myocytes, Cardiac / Q000378:metabolism*; D016328:NF-kappa B / Q000378:metabolism; D020556:Neutrophil Infiltration / Q000502:physiology; D047495:PPAR gamma / Q000172:deficiency / Q000378:metabolism / Q000502:physiology*; D013629:Tamoxifen
chemical_list: D016207:Cytokines; D004268:DNA-Binding Proteins; D018836:Inflammation Mediators; D016328:NF-kappa B; D047495:PPAR gamma; D013629:Tamoxifen